ADHD Advisory
ADHD Advisory
For immediate release
New cautions regarding rare heart-related risks for all ADHD drugs
OTTAWA - Health Canada has revised the prescribing and patient information for all drugs used for the management of ADHD (Attention Deficit Hyperactivity Disorder) and advises Canadians not to use them if they have high blood pressure, heart disease or abnormalities, hardening of the arteries or an overactive thyroid gland.
The new prescribing and patient information applies to both adults and children.
Standardized labeling that identifies risk factors for rare heart-related side effects, and new recommendations to physicians have been added to the prescribing information for the following drugs, and for any products containing these drugs:
| ADDERALL XR® | mixed salts amphetamine extended-release |
|---|---|
| ATTENADE™ | dextromethylphenidate [approved by Health Canada, but the manufacturer has not marketed in Canada] |
| BIPHENTIN® | methylphenidate controlled release [approved by Health Canada, but the manufacturer has not marketed in Canada] |
| CONCERTAâ | methylphenidate extended release |
| DEXEDRINE® | dextroamphetamine |
| RITALIN® | methylphenidate |
| RITALIN SR® | (methylphenidate extended release) |
| STRATTERA® | atomoxetine |
â Trademark used under licence to Janssen-Ortho Inc.
 |
|
 |
 |
 |
|
 |
|
 |
|
 |
|
